Cadrenal Therapeutics, Inc. · NASDAQ:CVKD
Cadrenal Therapeutics — Investor Presentation (May 2026)
18 slides from Cadrenal Therapeutics's investor presentation, May 2026
Slide 1: Novel 12-LOX Inhibitor Targeting the Root Cause of HIT
Novel 12-LOX Inhibitor Targeting the Root Cause of HIT (heparin-induced thrombocytopenia) Intended to Reduce Life-Threatening Thrombotic Events Without Increasing Bleeding Risk May 2026 Nasdaq: CVKD
Slide 2: Forward-looking Statements
Forward-looking Statements This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we
Slide 3: Investment Highlights
Investment Highlights A differentiated, capital-efficient Phase 3 opportunity in a high unmet need indication First-in-class mechanism targeting immune-driven platelet activation (12-LOX) Additive to current therapy with potentially superior clinical outcomes Compelling clinical signal: >25% absolut
Slide 4: Heparin Induced Thrombocytopenia (HIT)
Heparin Induced Thrombocytopenia (HIT) Severe immune-mediated condition with high thrombotic event rate, morbidity, and cost burden Heparin is the most widely used HIT versus non-HIT in-hospital anticoagulant in Heparin treated patients 12M patients annually are treated in the U.S. undergoing cardia
Slide 5: High Clinical and Economic Burden of HIT
High Clinical and Economic Burden of HIT Outcome Incidence HIT vs. Non-HIT • HIT outcomes can be catastrophic (Multiple of Incidence1) with a substantial increase in Thromboembolic Events 6.0 – 8.5x complications. Amputation 4.3 – 6.0x • Incremental hospital cost burden of HIT is dramatic at between
Slide 6: Large and Underserved HIT Market Opportunity
Large and Underserved HIT Market Opportunity Meaningful commercial opportunity in a well-defined hospital setting HIT Patient Population (U.S.)1 HIT Market Landscape & CAD-1005 Opportunity Suspected Acute 300K • 154K total HIT addressable population in US Epidemiology1 • Increasing to 188K (+22%) by
Slide 7: CAD-1005 Overview
CAD-1005 Overview The only selective 12-LOX inhibitor in clinical trials - with HIT as an ideal entry indication What is 12-LOX and why is it important in HIT ? • 12-LOX is an enzyme primarily expressed in platelets that amplifies FcγRIIa-mediated platelet activation • In HIT, 12-LOX is a critical l
Slide 8: Thrombus Formation in HIT
Thrombus Formation in HIT A Vicious Cycle Driven By Platelet Activation via FcɣRIIa Receptors Standard of Care (argatroban, bivalirudin) only targets thrombus formation A vicious cycle Argatroban Bivalirudin 8
Slide 9: Thrombus Formation in HIT
Thrombus Formation in HIT A Vicious Cycle Driven By Platelet Activation via FcɣRIIa Receptors CAD-1005 – A Novel Therapeutic Approach CAD-1005 is being Immune Complex Binding to studied for FcɣRIIa Activates 12-LOX Blocking platelet Inhibited by CAD-1005 CAD-1005 activation Interrupting the vicious
Slide 10: Phase 2 Trial
Phase 2 Trial Secondary endpoints provide evidence of reduction in thrombotic events on top of SOC Study type: randomized, blinded, placebo-controlled Phase 2 (only such trial ever done in HIT) Trial Design Dataset: 24 suspected HIT patients treated with background SOC anticoagulant therapy; primary
Slide 11: Planned Phase 3 Pivotal Study – CAD-1005 in HIT
Planned Phase 3 Pivotal Study – CAD-1005 in HIT Focus on clinically meaningful thrombotic events Design: Randomized, blinded, placebo-controlled, parallel group; 1:1 CAD-1005 vs. Placebo: background SOC Population: suspected HIT; enroll ~180 to yield ~120 Serotonin Release Assay (SRA+) for primary a
Slide 12: Phase 3 Design Considerations to Support Clinical Success
Phase 3 Design Considerations to Support Clinical Success Phase 2 learnings and FDA guidance Phase 2 (completed) Phase 3 Treatment Duration Until platelet recovery or up to 14 days 14 days/discharge Multiple Factors Support (acute phase) (acute and subacute in-hospital phase) Potential for Success S
Slide 13: Intellectual Property
Intellectual Property 12-LOX Program IP Status & Key Claims LOE Granted Patents* • CAD-1005 composition of matter 2034 (US, CA, EP, JP) • Regulatory Exclusivity: Orphan • 12-LOX inhibitors, IV drug designation and status in the • HIT method of use US and EU provides potential 7 and 10 years of marke
Slide 14: Key Upcoming Value Inflection Points
Key Upcoming Value Inflection Points Assuming financing completed July 2026 2026 2027 2028 2029 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Phase 2: Phase 3: Phase 3: Phase 3: 2 Publications First Patient In Interim Analysis Final Analysis 3Q26 2H-2027 Mid-2028 Mid-2029 Phase 2: Phase 3: Final F
Slide 15: Experienced Leadership
Experienced Leadership From discovery to commercial drug development Quang X. Pham James Ferguson, MD, FACC, FAHA Matthew Szot, CPA Jeff Cole Matt Boxer, PhD CEO & Founder, Chairman Chief Medical Officer Chief Financial Officer Chief Operating Officer EVP Corporate Development John R. Murphy Steven
Slide 16: Executive Summary
Executive Summary CAD-1005: First-in-class selective 12-LOX inhibitor designed to reduce life-threatening clots in HIT Large Unmet Need: HIT is a severe immune reaction to heparin, the most widely used in-hospital anticoagulant; 154K addressable patient population in the U.S. with a $1B to $1.4B+ an
Slide 17: Other Pipeline Programs
Other Pipeline Programs Program Target Indications Regulatory Strategy/Status Discovery Preclinical Phase I Phase II Phase III • FDA Orphan Drug End-stage Kidney Designation Granted Disease (ESKD) • FDA Fast Track Designation with AFib granted 11 clinical • Phase 2/3 ready studies Tecarfarin > 1,000
Slide 18: Contact Us:
Contact Us: Quang X. Pham CEO & Founder quang.pham@cadrenal.com Matthew Szot CFO matthew.szot@cadrenal.com 18
Cadrenal Therapeutics — Investor Presentation (May 2026) on 6ix